-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

Benzinga·09/30/2026 17:57:02
JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.